Risk factors for transplant-associated thrombotic microangiopathy (TA-TMA): a systematic review and meta-analysis

被引:2
|
作者
Guo, Mengting [1 ,2 ,3 ]
Qi, Jiaqian [1 ,2 ,3 ]
Hou, Qixiu [1 ,2 ,3 ]
Li, Xueqian [1 ,2 ,3 ]
Han, Yue [1 ,2 ,3 ,4 ,5 ]
机构
[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou, Peoples R China
[2] Soochow Univ, Inst Blood & Marrow Transplantat, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China
[3] Minist Hlth, Key Lab Thrombosis & Hemostasis, Suzhou, Peoples R China
[4] Soochow Univ, State Key Lab Radiat Med & Protect, Suzhou, Peoples R China
[5] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, 188 Shizi St, Suzhou 215006, Peoples R China
基金
中国国家自然科学基金;
关键词
Transplant-associated thrombotic microangiopathy; risk factors; meta-analysis; STEM-CELL TRANSPLANTATION; HUMAN CYTOMEGALOVIRUS-INFECTION; ENDOTHELIAL-CELLS; BONE-MARROW; PROPHYLAXIS; RECIPIENTS; INJURY; VIRUS;
D O I
10.1080/17474086.2023.2162501
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionTransplant-associated thrombotic microangiopathy (TA-TMA) is a severe hematopoietic stem cell transplantation complication with high mortality and a poor patient prognosis. The pathogenesis of TA-TMA is not yet clear. In previous studies, the conclusions of different centers remain controversial. We conducted a systematic review and meta-analysis of nine selected risk factors that might be associated with the onset of TA-TMA.Materials and MethodsPubMed databases were searched from their inception up to 15 September 2021, for relevant studies. The articles included unprocessed data related to one or more of the risk factors discussed in this meta-analysis, including recipient gender, donor type, graft source, pretreatment, infection, aGVHD, diagnosis, total body irradiation (TBI), and CMV infection. The outcome is the incidence rate (IR) of TA-TMA.Results and ConclusionsAccording to the sixteen articles included, risk factors included in this Meta-analysis included gender, unrelated donor source (95% CI: 1.29-2.01), graft source from peripheral blood stem cell (PBSC)(95% CI: 0.48-0.97), RIC/NMA, class II-IV aGVHD (95% CI: 2.22-4.78), nonmalignant disease, TBI. However, inconsistent diagnostic criteria for TA-TMA and the limited number of studies have an impact on the results of the study. More prospective cohort studies and More accurate diagnostic criteria are needed.
引用
收藏
页码:191 / 203
页数:13
相关论文
共 50 条
  • [21] Transplant-Associated Thrombotic Microangiopathy (TA-TMA) in a patient with acute GVHD after allogeneic hematopoietic stem cell transplantation successfully treated with eculizumab
    Donnini, I.
    Di Gioia, M.
    Nozzoli, C.
    Gozzini, A.
    Guidi, S.
    Saccardi, R.
    Bosi, A.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S577 - S578
  • [22] ECULIZUMAB PK/PD MODELING AND SIMULATION FOR PERSONALIZED DOSE ADJUSTMENT IN BLEEDING PATIENTS WITH STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA).
    Mizuno, K.
    Dandoy, C.
    Teusink-Cross, A.
    Davies, S.
    Vinks, A.
    Jodele, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S37 - S37
  • [23] HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA) HAS HIGH-RATE MORTALITY WHEN TREATED WITH CONVENTIONAL APPROACHES
    Iovino, L.
    Mazziotta, F.
    Orciuolo, E.
    Buda, G.
    Morganti, R.
    Caracciolo, F.
    Galimberti, S.
    Petrini, M.
    Benedetti, E.
    HAEMATOLOGICA, 2017, 102 : 168 - 169
  • [24] Risk factors for transplantation-associated thrombotic microangiopathy (TA-TMA): Analysis of twenty-five cases and matched controls.
    Daly, AS
    Hasegawa, WS
    Lipton, JH
    Messner, HA
    Kiss, TL
    BLOOD, 2001, 98 (11) : 193A - 193A
  • [25] RISK FACTORS FOR TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA) AMONG PATIENTS WITH PHILADELPHIA POSITIVE (PH plus ) LEUKEMIAS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANT
    Punatar, Sachin
    Kumbhalwar, Komal
    Kalantri, Siddhesh
    Gokarn, Anant
    Nayak, Lingaraj
    Chichra, Akanksha
    Mirgh, Sumeet
    Jindal, Nishant
    Mathew, Libin
    Kannan, Sadhana
    Khattry, Navin
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 515 - 515
  • [26] Incidence and Risk Factors of Transplantation-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis
    Van Benschoten, Victoria
    Roy, Cayla
    Gupta, Rohit
    Ouellette, Lara
    Hingorani, Sangeeta
    Li, Ang
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (05): : 266.e1 - 266.e8
  • [27] TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA) IN CHILDREN TREATED WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT): ONE CENTER STUDY
    Jarmolinski, Tomasz
    Rosa, Monika
    Bil-Lula, Iwona
    Korlaga, Joanna
    Kalwak, Krzysztof
    Ussowicz, Marek
    BONE MARROW TRANSPLANTATION, 2024, 59 : 612 - 612
  • [28] Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort
    Schoettler, Michelle
    Lehmann, Leslie E.
    Margossian, Steven
    Lee, Maia
    Kean, Leslie S.
    Kao, Pei-Chi
    Ma, Clement
    Duncan, Christine N.
    BLOOD ADVANCES, 2020, 4 (11) : 2536 - 2547
  • [29] Using Rheopheresis for stem cell Transplantation-Associated Thrombotic Microangiopathy (TA-TMA)
    Gonzalez-Vicent, Marta
    Herrero, Blanca
    Guillen, Maria
    Sevilla, Julian
    Angel Diaz, Miguel
    TRANSFUSION AND APHERESIS SCIENCE, 2013, 49 (02) : 234 - 237
  • [30] APPLICATION OF RECENTLY PROPOSED EBMT/ ASTCT/ CIBMTR/APCMT CONSENSUS RISK STRATIFICATION FOR TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA) IN CHILDREN
    Schoettler, Michelle
    Bryson, Elyse
    Spencer, Kathleen
    Qayed, Muna
    Chonat, Satheesh
    Westbrook, Adrianna
    Williams, Kirsten
    BONE MARROW TRANSPLANTATION, 2024, 59 : 118 - 119